Non-histaminic angioedema
diseaseOn this page
Also known as angioneurotic edemaangioneurotic oedemabradykinine-induced angioedemanon histamine-induced angioedema
Summary
Non-histaminic angioedema (MONDO:0019013) is a disease and 4 clinical trials. Top therapeutic interventions include conestat alfa and icatibant. A subtype of allergic urticaria — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe)
- Clinical trials: 4
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | Europe | Not yet validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | non-histaminic angioedema |
| Mondo ID | MONDO:0019013 |
| Orphanet | 658 |
| SNOMED CT | 41291007 |
| GARD | 0018701 |
| Is cancer (heuristic) | no |
Also known as: angioneurotic edema · angioneurotic oedema · bradykinine-induced angioedema · non histamine-induced angioedema
Disease family
This is a subtype of allergic urticaria. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › atopic eczema › allergic urticaria › non-histaminic angioedema
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00225147 | PHASE2/PHASE3 | COMPLETED | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
| NCT00262301 | PHASE3 | COMPLETED | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema |
| NCT00119431 | PHASE2 | COMPLETED | Kinetics, Efficacy and Safety of C1-Esteraseremmer-N |
| NCT00517582 | PHASE1 | TERMINATED | Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CONESTAT ALFA | 4 | 2 |
| ICATIBANT | 4 | 2 |
Related Atlas pages
- Drugs: Conestat Alfa, Icatibant